


## Stereocontrolled Synthesis of the C(1)–C(17) Half of Boromycin

James D. White,\* Mitchell A. Avery, Satish C. Choudhry, Om P. Dhingra, Myung-chol Kang, and Alan J. Whittle

Department of Chemistry, Oregon State University  
Corvallis, Oregon 97331

Received July 5, 1983


The ionophore boromycin (**1**)<sup>1</sup> consists of two stereochemically related halves linked head to tail to form a diolide, with a borate bridge spanning the macrocycle.<sup>2</sup> We recently described<sup>3</sup> the



reconstitution of **1** from a degradation product **2**,<sup>4</sup> in which the macrodiolide nucleus was first converted to a borate and then selectively esterified with D-valine. In parallel with these efforts, we have pursued syntheses of the two halves of **2**<sup>5</sup> via a route that permits convergence with lactones **3** and **4** derived by further degradation of **2**.<sup>2,3</sup> Hanessian et al.<sup>6</sup> have independently reported chiral syntheses of these lactones, and recently, Corey et al.<sup>7</sup> announced the total synthesis of aplasmomycin,<sup>8</sup> a symmetrical macrocyclic borate structurally allied to **1**.

A synthesis of the chiral C(11)–C(17) segment of **2** was achieved from 3-buten-2-ol via enantioselective epoxidation with

*tert*-butyl hydroperoxide in the presence of titanium tetraisopropoxide and diisopropyl D-(–)-tartrate.<sup>9</sup> The resulting epoxide **5**, which possessed the desired (2R,3S) configuration,<sup>10</sup> was alkylated with the tetrahydropyranyl ether of propargyl alcohol (*n*-BuLi, THF, –78 → 25 °C) to give **6** (91%). This acetylene was semihydrogenated (10% Pd/BaSO<sub>4</sub>, quinoline, MeOH), affording *cis* olefin **7** (98%), and the latter was converted directly to **8** (91%) with 2,2-dimethoxypropane (*p*-TsOH, MeOH, C<sub>6</sub>H<sub>6</sub>). In preparation for coupling with the C(3)–C(10) segment, **8** was transformed to allylic chloride **9** (83%) with *N*-chlorosuccinimide and dimethyl sulfide.<sup>11</sup>



Synthesis of the C(3)–C(10) moiety began from 3,3-dimethoxy-2,2-dimethylpropanol (**10**),<sup>12</sup> obtained via condensation of isobutyraldehyde with formaldehyde.<sup>13</sup> Oxidation of **10** (PCC) provided the malondialdehyde derivative **11** (66%, bp 55 °C (17 mm)), which was alkylated with the dianion<sup>14</sup> of tiglic acid (2.2 equiv of LDA, THF, –78 → 25 °C, 24 h) to give **12** (95%). This hydroxy acid was hydrogenated (94%, 10% Pd/C, EtOAc) and lactonized (DCC, DMAP) to yield **13** (80%) as a 40:60 mixture of *cis*/*trans* isomers.<sup>15</sup> Without separation, this mixture was taken to aldehyde **14** (TiCl<sub>4</sub>, AcCl, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 0.5 h)<sup>16</sup> and then to carboxylic acid **15** (RuCl<sub>3</sub>, NaIO<sub>4</sub>, CCl<sub>4</sub>, CH<sub>3</sub>CN, H<sub>2</sub>O; 68% from **13**),<sup>17</sup> which, upon esterification (CH<sub>2</sub>N<sub>2</sub>), furnished **16** (96%). Treatment of **16** with (2R,3R)-(–)-butanediol (camphorsulfonic acid, C<sub>6</sub>H<sub>6</sub>) afforded the ortho ester **17**<sup>18</sup> in 84% yield as a mixture of four diastereomers, in which the *trans*/*cis* ratio was 3.7:1.<sup>19</sup> Condensation of this mixture with the dianion<sup>20</sup> of methyl phenyl sulfone (1.5 equiv, 3 equiv of *n*-BuLi, THF, 0 °C) gave a mixture of keto sulfones (92%), from which the desired diastereomer **18** (mp 96–98 °C) was obtained (35% from **16**) by HPLC on  $\mu$ Porasil.

Alkylation of the enolate of **18** (1.06 equiv of *n*-BuLi, Me<sub>2</sub>SO–THF) with **9** in the presence of KI yielded **19** (97%) as a pair of diastereomers. The sulfonyl group was removed (Al/Hg,

(1) Hütter, R.; Keller-Schierlein, W.; Knusel, F.; Prelog, V.; Rodgers, G. C., Jr.; Suter, P.; Vogel, G.; Voser, W.; Zahner, H. *Helv. Chim. Acta* **1967**, *50*, 1533.

(2) Dunitz, J. D.; Hawley, D. M.; Miklos, D.; White, D. N. J.; Berlin, Yu.; Marušić, R.; Prelog, V. *Helv. Chim. Acta* **1971**, *54*, 1709.

(3) Avery, M. A.; White, J. D.; Arison, B. H. *Tetrahedron Lett.* **1981**, *22*, 3123.

(4) Marsh, W.; Dunitz, J. D.; White, D. N. J. *Helv. Chim. Acta* **1974**, *57*, 10.

(5) A portion of this work was communicated previously. See: White, J. D. "Abstracts of Papers", 179th National Meeting of the American Chemical Society, Houston, TX, March 24–28, 1980; American Chemical Society: Washington, DC, 1980; ORGN 48.

(6) (a) Hanessian, S.; Tyler, P. C.; Demailly, G.; Chapleur, Y. *J. Am. Chem. Soc.* **1981**, *103*, 6243. (b) Hanessian, S.; Delorme, D.; Tyler, P. C.; Demailly, G.; Chapleur, Y. *Can. J. Chem.* **1983**, *61*, 634.

(7) Corey, E. J.; Pan, B.-C.; Hua, D. H.; Deardorff, D. R. *J. Am. Chem. Soc.* **1982**, *104*, 6816. Corey, E. J.; Hua, D. H.; Pan, B.-C.; Seitz, S. P. *Ibid.* **1982**, *104*, 6818.

(8) Okazaki, T.; Kitahara, T.; Okami, Y. *J. Antibiot.* **1975**, *28*, 176. Sato, K.; Okazaki, T.; Maeda, K.; Okami, Y. *Ibid.* **1978**, *31*, 632.

(9) Martin, V. S.; Woodard, S. S.; Katsuki, T.; Yamada, Y.; Ikeda, M.; Sharpless, K. B. *J. Am. Chem. Soc.* **1981**, *103*, 6237.

(10) It was established by an independent synthesis of **5** that epoxidation had taken place in 91% enantiomeric excess. See: White, J. D.; Sheldon, B. G.; Kang, M.-c. *Tetrahedron Lett.*, in press.

(11) Corey, E. J.; Kim, C. U.; Takeda, M. *Tetrahedron Lett.* **1972**, 4339.

(12) Spath, E.; Pallan-Raschik, L. *Monatsh. Chem.* **1948**, *79*, 447.

(13) Hattori, S.; Tokizawa, M. Japan Pat. 21 687, 1970; *Chem. Abstr.* **1970**, *73*, 87460d.

(14) Katzenellenbogen, J. A.; Crumrine, A. L. *J. Am. Chem. Soc.* **1976**, *98*, 4925.

(15) Treatment of this mixture with LDA–THF gave an equilibrium composition of 80:20 in favor of *trans*-**13**.

(16) Berkowitz, W. F.; Choudhry, S. C.; Hrabie, J. A. *J. Org. Chem.* **1982**, *47*, 824.


(17) Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. *J. Org. Chem.* **1981**, *46*, 3936.

(18) Saucy, G.; Borer, R.; Trullinger, D. P.; Jones, J. B.; Lok, K. P. *J. Org. Chem.* **1977**, *42*, 3206.

(19) Configurational equilibrium at the center  $\alpha$  to the lactone carbonyl is probably attained in this reaction via a ketene acetal intermediate.

(20) Kondo, K.; Tunemoto, D. *Tetrahedron Lett.* **1975**, 1397.

THF-H<sub>2</sub>O (10:1), 75 °C, 1 h) to furnish **20** as an oil ( $[\alpha]_D^{23} +3.5^\circ$ ) in 75% yield from **18**. Reduction of this ketone (NaBH<sub>4</sub>, MeOH, 25 °C) gave a mixture of **21** and **22** (98%; 2:1 respectively), the acetates of which (Ac<sub>2</sub>O, pyridine, DMAP) were easily separated. The 7*S* acetate **23** underwent hydrolysis (*p*-TsOH, THF-H<sub>2</sub>O (4:1), 56 °C, 12 h) to **24**, which was saponified (NaOH, THF-H<sub>2</sub>O, 25 °C, 3 h) and acidified (5% aqueous HCl) to provide **4** (91% from **23**), identical with the degradation product from boromycin.<sup>3</sup> For a rigorous comparison with naturally derived material, synthetic **4** was converted to triacetate **25** (68%,




$[\alpha]_D^{20} +14.2^\circ$ ; Ac<sub>2</sub>O, pyridine, DMAP), which was spectroscopically identical with the substance ( $[\alpha]_D^{20} +17.6^\circ$ )<sup>6b</sup> obtained from **1**.

With the configuration at the five chiral centers in this segment authenticated, attention was turned to its homologation in order to complete the C(1)-C(17) perimeter of **2**. After protection of **4** as its bis(*tert*-butyldimethylsilyl) ether **26** (excess TBDMSCl, imidazole, DMF, 48 h), the latter was treated with 2,2-dimethoxypropane (*p*-TsOH, C<sub>6</sub>H<sub>6</sub>-MeOH) to give a quantitative yield of **27**. This ester was saponified (20% aqueous NaOH, MeOH, followed by 2% HCl, 0 °C), and the derived carboxylic acid **28** was converted to **29** (carbonyldiimidazole, THF). Acylation of the enolate of methyl methoxyisopropylglycolate<sup>21</sup> (LDA, THF, -78 °C, 10 min) with **29** afforded **30** as a C(2) epimeric mixture in 35% overall yield from **27**.<sup>22</sup> Stereochemical inhomogeneity at this stage is probably of no consequence, since it has been demonstrated in the synthesis of aplasmomycin that borate formation from the macrocyclic tetraol is accompanied by epimer-

(21) Prepared by exposing a mixture of methyl glycolate and 2-methoxypropane to the vapor of POCl<sub>3</sub> (Caution: exotherm).

(22) For a recent account of the elegant approaches by Hanessian to the two halves of boromycin, see: Hanessian, S.; Delorme, D.; Tyler, P. C.; Demailly, G.; Chapleur, Y. In "Current Trends in Organic Synthesis"; Nozaki, H., Ed.; Pergamon Press: Oxford, U.K., 1983; p 205.



ization at C(2) to the natural *R* configuration.<sup>7</sup>

The synthesis of **30** permits access to a fully functionalized subunit of **2** with rigorously defined stereochemistry and also opens a prospective route to the second half of boromycin.

**Acknowledgment.** We are grateful to Bernard G. Sheldon, Paul R. Johnson, and Jeffrey Fitzner for experimental assistance. Financial support was provided by the National Institutes of Health (Grant AI 10964).

### New Mechanism-Based Serine Protease Inhibitors: Inhibition of Human Leukocyte Elastase, Porcine Pancreatic Elastase, Human Leukocyte Cathepsin G, and Chymotrypsin by 3-Chloroisocoumarin and 3,3-Dichlorophthalide

J. Wade Harper, Keiji Hemmi, and James C. Powers\*

School of Chemistry  
Georgia Institute of Technology  
Atlanta, Georgia 30332

Received May 23, 1983

Mechanism-based irreversible inhibitors, which have been reported for porcine pancreatic (PP) elastase and bovine pancreatic chymotrypsin A<sub>1</sub>, include halo enol lactones and 6-chloropyrones.<sup>1</sup> Human leukocyte (HL) elastase and cathepsin G are related serine proteases which are involved in the connective tissue destruction that occurs in emphysema and various inflammatory diseases. Both enzymes are inhibited reversibly by heterocyclic structures such as benzoxazinones<sup>2</sup> and benzisothiazolinones,<sup>3</sup> and this

(1) Westkaemper, R. B.; Abeles, R. H. *Biochemistry* **1983**, *22*, 3256-3264. Vilkas, M. In "Enzyme-Activated Irreversible Inhibitors"; Seiler, N., Jung, M. J.; Koch-Weser, J., Eds.; Elsevier/North Holland Biochemical Press: New York, 1978; pp 323-335. White, E. H.; Jelinski, J. S.; Politzer, I. R.; Branchini, B. R.; Roswell, D. F. *J. Am. Chem. Soc.* **1981**, *103*, 4231-4239. Chakravarty, P. K.; Krafft, G. A.; Katzenellenbogen, J. A. *J. Biol. Chem.* **1982**, *257*, 610-612. Moorman, A. R.; Abeles, R. H. *J. Am. Chem. Soc.* **1982**, *104*, 6785-6786. Alazard, R.; Bechet, J.; Dupaix, A.; Yon, J. *Biochim. Biophys. Acta* **1973**, *309*, 379-396.

(2) Teshima, T.; Griffin, J. C.; Powers, J. C. *J. Biol. Chem.* **1982**, *257*, 5085-5091.